| Description |
Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2]. |
| Cat.No |
DC65470 |
| Name |
Belantamab Mafodotin |
Chemical Properties
| CAS |
2050232-20-5 |
|
| Synonyms |
Belantamab Mafodotin;Belantamab mafodotin-blmf;Blenre |
| pH value |
Corresponds to reference standard: PASS |
| Non-reduced CE-SDS |
>95% |
| SEC-HPLC |
>95% |
| Isoelectric Point |
Corresponds to reference standard |
| Bacterial Endotoxins Test |
|
| Residual Proteins of Host Cell |
|
| Exogenous Residual DNA |
|
| Residual protein A |
|
| Biological Activity |
|
| Osmolality |
Corresponds to reference standard: PASS |
| Peptide mapping |
Corresponds to reference standard: PASS |
| N-terminal sequence |
Corresponds to reference standard: PASS |
References
|
[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.
[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. |
|
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470
Email:
sales@dcchemicals.com
order@dcchemicals.com
Website:
www.dcchemicals.com
|
